Name:

Nimenrix (Nimenrix)

Abbreviation:

MenACWY - Meningococcal conjugate vaccine for serogroups ACWY.

General Overview:

Nimenrix is an inactivated vaccine that is considered one of the important preventive measures against meningococcal infections.

The vaccine is produced using modern biotechnological methods - it contains polysaccharide antigens from meningococcal groups A, C, W, and Y, which are conjugated to a protein carrier to enhance the immune response.

Nimenrix does not contain live microorganisms and is produced in the form of a lyophilized powder and a diluent, which ensures the stability and effectiveness of the vaccine during storage.

The vaccine is stored at a temperature between 2°C and 8°C and does not require freezing; it is presented in pre-filled syringes, which simplifies the injection process and ensures accurate dosing.

The safety and immunogenicity of Nimenrix have been demonstrated in numerous clinical studies across different age groups, and accordingly, it is widely used against meningococcal infections.